Baron Health Care Fund made the following comment about Bio-Techne Corporation (NASDAQ:TECH) in its Q3 2023 investor letter:
"Another material detractor in the sub-industry was Bio-Techne Corporation (NASDAQ:TECH), a leading developer and manufacturer of reagents, instruments, and services for the life sciences research, diagnostics, and bioprocessing markets. Bio-Techne’s shares were pressured by various headwinds in the life sciences tools end market including reduced biotechnology funding, continued inventory destocking by customers, and a slowdown in China."
https://finance.yahoo.com/news/various-headwinds-pressured-bio-techne-090109193.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.